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This study examines the opinions and usage of Noninvasive Prenatal Screening 
(NIPS) by genetic counselors (GCs). One hundred and three GCs were surveyed regarding 
their current practice involving NIPS, their opinion on offering it to all patients regardless of 
a priori risk, and their thoughts on future implications of the screening test. A significantly 
greater number of GCs are offering NIPS to all patients and believe in the implementation 
of universal NIPS, or NIPS for any patient no matter their risk, relative to a similar sample 
surveyed in 2015. Discordance between practice and belief remains an issue. Now more 
patients are being offered NIPS with a microdeletion panel. Favoring universal NIPS was 
negatively associated with number of years in practice as well as the percentage of their 
patients insured through government funding. The most common qualitative response from 
both those who do and do not believe in the use of NIPS universally concerned the clinical 
validity of NIPS compared to other screening techniques. There remains no consensus 
among GCs on how to best utilize NIPS: for what indications, for which conditions, in 
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Since the introduction of noninvasive prenatal screening into clinical care in 2011, 
professional organizations have been analyzing and assessing its use to define practice 
guidelines. In the seven years since its commercialization, opinions about the test’s clinical 
utility have changed rapidly. In 2012, the American College of Obstetricians and 
Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) approved of 
NIPS as a first-line aneuploidy test only for high-risk patients (ACOG and SMFM 2012). 
Despite these recommendations, the use of NIPS in the general population continued to 
grow, as did its role in the public eye as the “gender test.” In 2015, for her graduate thesis, 
Emily Suskin surveyed practicing prenatal genetic counselors regarding NIPS. The survey 
asked about their use of NIPS, their opinions on the universal implementation of NIPS, and 
their ideal aneuploidy screening. This research was published in the Journal of Genetic 
Counseling in 2016 and was seen as an extension of research completed by Horsting et al. in 
2014 (Horsting et al. 2014; Suskin et al. 2016) 
Since the survey completed by Suskin et al. in 2015, the American College of Medical 
Genetics and Genomics (ACMG) has amended its position statement regarding NIPS, 
stating that NIPS can be offered to all patients regardless of a priori risk along with all other 
screening options (Gregg et al. 2016). The proficiency of the technology and the range of 
conditions screened using NIPS have also evolved. It makes sense, therefore, to revisit the 
issue in order to assess changes in opinion and practice in the GC community regarding the 
updated use of NIPS. 
Note: Noninvasive prenatal screening for fetal aneuploidy has many names and 
abbreviations. Noninvasive prenatal testing (NIPT) and cell-free fetal DNA (cffDNA) are 
other commonly used terms. In keeping with ACMG we	will use the term NIPS as it 
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emphasizes the nature of the test as screening rather than diagnostic, except in the cases of 
direct quotations. 
Current Guidelines 
In 2016, the American College of Medical Genetics updated their position statement 
to propose that regardless of a priori risk, all women, who are not significantly obese, be 
offered NIPS as the most sensitive screening test available for detecting trisomies 13, 18, and 
21 (Gregg et al. 2016). So long as patients are consented with proper pre-test counseling, the 
ACMG guidelines state all patients should be made aware of the options for expanded NIPS 
for clinically relevant copy-number variants and sex chromosome abnormalities. Although, 
ACMG does not recommend screening for other autosomal aneuploidies, genome-wide 
copy number variants (CNV) screening, or the use of NIPS for sex selection (Gregg et al. 
2016). The ACMG recommendations differ from the most recent guidelines published by 
the National Society of Genetic Counselors (NSGC), which suggested NIPS only be offered 
to women at high-risk for having babies with chromosomal aneuploidy (Wilson et al. 2013) 
and conflicts with its own October 2016 position statement recommending that NIPS be 
offered to all pregnant patients (NSGC 2016). In 2015, the American Congress of Obstetrics 
and Gynecology (ACOG) and Society for Maternal Fetal Medicine (SMFM), in a joint 
opinion, said all women can be offered NIPS, with the caveat that it is not the standard of 
care (ACOG and SMFM 2015). Experts consistently agree that NIPS should not be treated 
as a substitute for invasive diagnostic techniques. 
There are limitations to NIPS as a screening test. A fetal fraction of 4% is generally 
thought to be the minimum threshold for accurate detection, but both overestimation and 
underestimation of fetal fraction can be problematic: overestimates of fetal fraction can lead 
to false positive results and underestimates can lead to sample rejection or no-call results 
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(Kinnings et al. 2015). NIPS technology is not effective in certain pregnancies, restricting 
them to traditional screens. Stretches of homozygosity between maternal and fetal genomes 
render genomic imbalance, copy number detection, and small deletions and duplications 
undetectable within those regions (Gregg et al. 2016). NIPS is not always made available to 
women who have had organ transplants from male donors or who have conceived using 
donor oocytes (Gregg et al. 2016). It is not possible to identify the fetus responsible for an 
abnormal NIPS result in multiple gestation pregnancies or pregnancies with “vanishing 
twins” and limited data exists on overcoming this issue. Despite a detection rate argued to be 
higher than biochemical and sonographic aneuploidy screening methods for twins, the 
known specificity and sensitivity of NIPS in multiple gestations is still unclear (Sachs et al. 
2015). 
Comparing Current Screening Options 
Many providers, including the majority of genetic counselors that participated in the 
Suskin et al. study, still see NIPS solely as one part of a stepwise care process. It has been 
argued that doing NIPS secondarily to traditional first trimester screens, which measure 
PAPP-A and ß-hCG biochemical marker levels and nuchal translucency, may actually be 
more problematic than useful. Multiple screens create a lengthier, potentially more 
expensive, three-step process where the patients’ choices may be impacted by timeline 
(Dondorp et al. 2015).  
NIPS is the most accurate method of noninvasive detection available for the 
classically screened fetal aneuploidies (trisomies 13, 18, and 21). In validation studies of 
NIPS for Down syndrome caused by true trisomy 21, translocations, and trisomy 21 
mosaicism, the screening had a detection rate and clinical specificity, or true negative 
identification rate, of 99%. Mosaic and translocation-caused Edwards and Patau Syndromes, 
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trisomies 18 and 13, respectively, had detection and specificity rates between 80-100% 
(Gregg et al. 2016). With regard to positive predictive value (PPV), NIPS was superior to 
conventional screens for Down syndrome (80.9 vs. 3.4%, N=15,841), Patau syndrome (33–
90% vs. 14%,), and Edwards syndrome (50–70% vs. 3.4%) (Gregg et al. 2016). The negative 
predictive value for NIPS also has reached nearly 100% for all three trisomies. NIPS, unlike 
traditional screens, is also clinically available for the detection of trisomies 9, 16, and 22, as 
well as multiple microdeletion syndromes (Sachs, et al., 2015), including but not exclusive to: 
22q11.2 deletion syndrome, cri-du-chat (5p), 1p36 deletion syndrome, Prader-Willi and 
Angelman (15q) syndromes. All of these have a range of outcomes that are complex and 
often cause intellectual disability.  
Genetic Counselors and NIPS 
A 2014 study of 236 genetic counselors provided a baseline for studying the use of 
NIPS by GCs (Horsting et al. 2014). At that point, few counselors reported offering NIPS to 
all patients (3.9%) as opposed to high-risk patients only (88.2%), though when asked, 89.4% 
of respondents agreed, “cffDNA testing will largely replace other screening testing” 
(Horsting et al., 2014). Between October 2012, when Horsting’s data were collected and 
January 2015, opinions had already begun to change. Suskin reported that 11% of GCs 
offered NIPS to all prenatal patients, and 37.8% offered the screening to low-risk patients if 
they requested it (Horsting et al. 2014; Suskin et al. 2016). Barriers to universal access to 
NIPS, identified by the Suskin study, include perceived lack of provider knowledge, necessity 
to educate providers, and patient education (Suskin et al. 2016). 
A 2016 study by Morrow showed a trend toward offering NIPS regardless of a priori 
risk, in data collected only eleven months after Suskin’s survey, Of all respondents, 36% 
reported offering NIPS to all patients (Morrow 2016). Additionally, 16% of respondents 
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stated they were also offering NIPS with microdeletion/microduplications to all patients, 
and 34% to high-risk patients only (Morrow 2016).  While the Horsting and Suskin studies 
did not specifically ask about offering CNV through NIPS this level of use indicates a 
further shift towards acceptance of NIPS as a good screening option for all women. 
Studies of other professionals 
Due to the workflow of most prenatal centers, many patients are not seen by genetic 
counselors; therefore, the number of low-risk patients offered NIPS will most likely depend 
on other medical professionals including OB/GYNs, Maternal-Fetal Medicine specialists 
(MFMs), and Certified-Nurse Midwives. Many recent studies have looked at these providers 
to examine whether their practice is in line with ACOG/SMFM guidelines and where they 
see the future of NIPS heading.  
A 2014 study looked at 278 MFM physicians to examine three aspects of NIPS: 
current use, ideal use, anticipated use (Haymon et al. 2014).  Data collection occurred in 
November and December 2012, within two months of the data from GCs in Horsting et al., 
which makes for some easy comparisons (Haymon et al. 2014; Horsting et al. 2014). At the 
time of the survey only 5% of MFMs offered NIPS to all patients, compared to 3.9% of 
GCs. Although a limited number of MFMs reported using NIPS for all patients, a slight 
majority, 51%, foresaw it replacing maternal serum screening in the future (Haymon et al. 
2014).  
In another study of prenatal physicians, Brewer et al. also chose to compare current 
use with ideal use; 72% believed NIPS should be offered to all patients regardless of a priori 
risk, while in reality only two-thirds were offering it to all patients. An additional question 
provided a small insight into this discrepancy: “81.5% of providers would use NIPT as a 
first-line screening for all of their patients if insurance covered it” (Brewer et al. 2017).  
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Many of these studies bring up concern over providers understanding the test basics 
of NIPS. One study found that 97.4% of MFMs correctly stated that NIPS should be used 
as a screening test (Swaney et al. 2016). Yet two other studies showed a self-reported 14.6% 
and 13% of MFMs offered NIPS as a diagnostic test (Brewer et al. 2017; Haymon et al. 
2014). This is especially concerning, if in fact providers are offering NIPS as a diagnostic 
test, given that the MFMs also reported only 81.6% of their patients are being referred to 
GCs for post-test counseling (Haymon et al. 2014). These studies demonstrate the necessity 
of GCs in the patient education process, and the dearth of knowledge some OBs and MFMs 
have about the tests they offer.  
Purpose of the Study 
The technology and scope of conditions for which patients are screened using NIPS 
has continued to evolve since the Suskin et al. study in 2015. Earlier studies suggest that 
providers have increasingly begun offering NIPS to all prenatal patients, as opposed to only 
those at higher risk. Yet, the genetics community has not reached consensus on how best to 
implement this change, or on whether it should be made at all. Concerns over the way the 
test is being presented to patients have given pause to those who would advocate for NIPS 
as first-tier testing for fetal aneuploidy (Suskin et al. 2016). Barriers to universal NIPS, 
including cost, are lessening (Chitty et al. 2016; Fairbrother et al. 2016), but ensuring patients 
are getting proper education prior to testing and upon return of results is still a top priority.  
To shed light on the rapidly changing state of clinical care, we undertook an update to the 
survey by Suskin et al. looking at current and comparative NIPS utilization, opinions on 









All genetic counselors whose jobs included prenatal counseling and who were 
members of NSGC were eligible to participate. 
Instrumentation 
The survey consisted of 41 multiple-choice, select-all-that-apply, and free-response 
questions focused on the participants’ use of NIPS, their opinions on NIPS, including how 
their views and practice may conflict, and how, if at all, they believe the usage of NIPS will 
change in the future. Some of the questions were based on the survey questions by Suskin et 
al (2016). The survey was administered through SurveyMonkey. No IP addresses were 
collected, participants were not asked any identifying questions, participants could opt out at 
any time, and only one question was mandatory.  
Procedures 
The Institutional Review Board at Sarah Lawrence College approved the study on 
January 1, 2018. Invitation to participate was distributed through the NSGC Student 
Research Project Program using the NSGC Listserv (n= 3704 initial) February 13, 2018 with 
a follow-up invitation on February 27, 2018. The survey remained open until March 6, 2018. 
Data Analysis 
A total of 105 submissions were received. The data of two respondents were 
excluded due to non-descriptive answers (n = 103). The open rate was for the first email was 
26.8% (967) and 23% (838) for the reminder email. Data analysis was performed 
independently for each question, as participants were not required to answer all questions. 
Descriptive statistics were calculated for each quantitative question using SurveyMonkey, 
Microsoft Excel, and SPSS. The qualitative data were analyzed using an interpretive content 
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method (Patton 2002). The research team identified emergent themes and sub-themes 
among the responses. First, each researcher coded responses individually. Matching themes 
were identified and those themes that were not exact matches were compared and agreed 
upon by consensus. 
  




Change Over Time 
 Participants were asked to describe differences, if any, they have noticed 
corresponding to changes in guidelines. In addition, responses to identical or similar 
questions as those in the Suskin et al. study were compared to identify any changes in 
practice and genetic counselors’ opinions since 2015. Data regarding these changes are 
represented in Figures 1 – 3. The study responses suggest a shift toward universal NIPS, in 
both the opinions on and the use of the screening. Genetic counselors noted both positives 
and negatives to the continued expansion of NIPS; most of these were in line with 
qualitative data from the previous study.  
Demographics 
 Participants answered questions regarding their years of experience, practice setting, 
and patient load. Select demographic data can be seen in Table I and Figure 4. Complete 
data can be seen in Appendix A. 
Current Practice 
 Respondents were asked about their current use of NIPS and their opinions on best 
practices in prenatal screening. Survey questions focused on the circumstances under which 
NIPS is offered at their institution, and GCs’ use of alternative prenatal tests. Participants 
also had the opportunity to reflect upon their use of NIPS and whether or not that reflected 
their views of best practices. Responses to questions about current use and opinions may be 
viewed in Tables II – V. Full responses pertaining to current practice question can be seen in 
Appendix B.  
Future Use  
 Survey respondents were asked under what circumstances they would offer 
additional types of NIPS (i.e. for other conditions, for whole genome or whole exome 
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study). A follow-up qualitative question asked participants to expound upon their views on 
the continued expansion of NIPS, these results may be seen in Table VI and Figure 5. 
Complete tables can be seen in Appendix C.  
	
Figure 1. Do you believe that NIPS should be offered universally (i.e. to any pregnant woman, regardless of 




Figure 2. Do you offer NIPS to ALL patients, regardless of risk? a. Represents respondents from 































Figure 3. Use of NIPS with microdeletion by year. (Chi-square = 16.89 (df=1), p<.001). 
 
Table I: Demographic Information 
Questions Answers na (%) 
Are you a certified genetic counselor? (N=103) 
Yes 103 (100%) 
No 0 (0.00%) 
How many years have you been a practicing GC? (In years) (N=103) 
Less than 3  37 (35.92%) 
3 - 4 6 (5.83%) 
5 - 6 10 (9.71%) 
7 - 10 10 (9.71%) 
11 - 15 7 (6.80%) 
16 - 20 13 (12.62%) 
More than 20 20 (19.42%) 
In what country do you work? (N=103) 
United States 99 (96.12%) 
Canada 3 (2.91%) 
                                                                                 Other (Please Specify)  
Australia 
1 (0.97%) 
In which NSGC practice region do you work? b, c (N=100) 
Region 1 11 (11.00%) 














































NIPS: a survey of opinions and uses by genetic counselors  
	
14 
Region 3 8 (8.00%) 
Region 4 34 (34.00%) 
Region 5 6 (6.00%) 
Region 6 24 (24.00%) 
On average how many prenatal patients do you counsel in a week? (N=103) 
< 5 10 (9.71%) 
5 - 9 21 (20.39%) 
10 - 14 31 (30.10%) 
15 - 19 29 (28.16%) 
≥ 20 12 (11.65%) 
Which of these best describes your primary work place? (N=100) 
University Medical Center 40 (40.00%) 
Private Practice 18 (18.00%) 
Private Hospital 18 (18.00%) 
Public Hospital 14 (14.00%) 
Community Hospital 2 (2.00%) 
Diagnostic Laboratory - Commercial 2 (2.00%) 
Health Maintenance Organization (HMO) 2 (2.00%) 
Government or Military Center 0 (0.00%) 
Other (please specify) 
Non-profit 
Private MFM office 





In what setting do you primarily practice? (N=102) 
Urban 65 (63.73%) 
Suburban 33 (32.35%) 
Rural 4 (3.92%) 
Approximately what portion of your patients have coverage through state or federal insurance programs 
(Medicaid or Medicare)? (N=100) 
< 25% 22 (22.00%) 
25 - 49% 47 (47.00%) 
50 - 75% 22 (22.00%) 
> 75% 9 (9.00%) 
Approximately what percentage of the patients offered NIPS at your center/institution are seen by genetics 
prior to testing? (N=94) 
< 25% 15 (15.96%) 
25 - 49% 5 (5.32%) 
50 - 75% 13 (13.83%) 
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> 75% 61 (64.89%) 
a Subtotal of respondents. b NSGC practice regions are defined as follows: 
Region 1: CT, MA, ME, NH, RI, VT, CN Maritime Provinces  
Region 2: DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec  
Region 3: AL, FL, GA, KY, LA, MS, NC, SC, TN 
Region 4: AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario  
Region 5: AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Saskatchewan  
Region 6: AK, CA, HI, ID, NV, OR, WA, British Columbia 
c Responses calculated based on two questions, “In which American state/territory do you 
primarily work?” and “In which Canadian province/territory do you primarily practice?” 
 
Table II: Current Practices and Opinions 
Questions Answers  na (%) 
Do you believe that NIPS should be offered universally (i.e. to any pregnant woman, regardless of a priori 
risk)? (N = 100) 
Yes 67 (67.00%) 
No 33 (33.00%) 
Does your institution currently offer NIPS? (N=98) 
Yes 97 (98.98%) 
No 1 (1.02%) 
Do you offer NIPS to ALL patients, regardless of risk? (N=96)   
Yes 52 (54.17%) 
No 44 (45.83%) 
To whom do you offer NIPS? (Select all that apply)b (N=46)  
Patients with a high-risk screen (NT, FTS, Quad, Sequential) 46 (100.00%) 
Patients over 35 44 (95.65%) 
Patients with a previous pregnancy affected with an aneuploidy 44 (95.65%) 
Patients who inquire about the test 24 (52.17%) 
Patients with recurrent miscarriage 8 (17.39%) 
Patients with family history of other genetic conditions 6 (13.04%) 
Patients interested in early detection of fetal sex 5 (10.87%) 




Do you generally combine the use of NIPS with other aneuploidy screening options? (N=95) 
Yes 58 (61.05%) 
No 37 (38.95%) 
For each sub-type of NIPS, check if you agree with the statement “I offer to all patients” c 
Classic Aneuploidy Screening (Trisomy 13, Trisomy 18, Trisomy 21) 
(N=91) 
45 (49.45%) 
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Sex Chromosomes (N=91) 55 (60.44%) 
Early Pregnancy Loss Chromosomes  (Trisomy 9, Trisomy 16, Trisomy 22) 
(N=85) 
8 (9.41%) 
Microdeletion Syndromes (limited panel) (N=89) 16 (17.98%) 
Whole Genome Copy Number Variant Screening (N=88) 1 (1.14%) 
Single gene conditions (N=89) 0 (0.00%) 
For each sub-type of NIPS, check if you agree with the statement “Not currently offered at this center” c  
Classic Aneuploidy Screening (Trisomy 13, Trisomy 18, Trisomy 21) 
(N=91) 
0 (0.00%) 
Sex Chromosomes (N=91) 0 (0.00%) 
Early Pregnancy Loss Chromosomes  (Trisomy 9, Trisomy 16, Trisomy 22) 
(N=85) 
53 (62.35%) 
Microdeletion Syndromes (limited panel) (N=89) 23 (25.84%) 
Whole Genome Copy Number Variant Screening (N=88) 50 (56.82%) 
Single gene conditions (N=89) 55 (61.80%) 
Approximately what percent of patients have diagnostic testing? (Amniocentesis or CVS) (N=86) 
< 25% 66 (76.74%) 
25 - 49% 14 (16.28%) 
50 - 74% 4 (4.65%) 
> 75% 2 (2.33%) 
a Subtotal of respondents. b This question was only asked to those who stated they do not 
offer NIPS to all patients. c  Responses compiled from matrix question “Please explain your 
current use of NIPS for each category of conditions?”   
 
  




Figure 4. Response to “Do you believe that NIPS should be offered universally (i.e. to any pregnant 
woman, regardless of a priori risk)?” based on years in practice (N = 100). (r (99) = -.21, p<.05). 
 
Table III: Opinion on Universal NIPS by Those Who Offer NIPS to All Patients 
Regardless of Risk 
Do you think NIPS should be 
offered universally? 
Currently Offer NIPS to All 
Regardless of Risk 
Do Not Offer NIPS to 
All 
Yes 92.3% (48) 36.4% (16) 
No 7.7% (4) 63.6% (28) 
Total 100.0% (52) 100.0% (44) 
Chi-Square = 33.57, (df=1), p <.001 
 
Table IV: Subtypes of NIPS Offered To All Patients Compared to Opinion On Universal 
NIPS 
NIPS Subtype 
NIPS Should Be 
Offered Universally 
NIPS Should Not Be 
offered Universally 
Classic aneuploidy (N=91)* 36 (60%) (n=60) 9 (29.03%) (n=31) 
Sex Chromosomes (N=91)*** 45 (75%) (n=60) 10 (32.26%) (n=31) 
Early Pregnancy Loss (N=85) n.s. 7 (12.28%) (n=57)  1 (3.57%) (n=28) 
Microdeletions (N=89)* 15 (25.42%) (n=59) 1 (3.33%) (n=30) 
Copy Number Variants (N=88) n.s. 1 (1.69%) (n=59) 0 (0.00%) (n=29) 
Single Gene Conditions (N=89) n.s. 0 (0%) (n=59) 0 (0%) (n=30) 















































Table V: Free Response on Opinions and Use of NIPS 
Question Theme  na (%)  
Please explain why you think NIPS should be offered universally … (N=58) 
[Comments by theme] 
NIPS is superior to traditional screening options  44 (74.58%) 
Offer all screening choices 11 (18.64%) 
Need for pre-test counseling by GC 7 (11.86%) 
Emphasis placed on limitations of NIPS 7 (11.86%) 
Please explain why you think NIPS should not be offered universally…(N=19) 
[Comments by theme] 
Data does not show superior test validity in low-risk populations 13 (68.34%) 
Use of test to detect gender/sex 5 (26.32%) 
Lack of insurance coverage, cost is prohibitory 4 (21.05%) 
Want values from other screening 3 (15.79%) 
Providers do not have sufficient or accurate knowledge about NIPS 3 (15.79%) 
NIPS will be universal in the future, inevitable 3 (15.79%) 
Please explain the difference in your practice of offering NIPS and your opinion on whether it should be 
offered to all patients … (N=20)b  
[Comments by theme] 
Decision was made by others are the institution/practice  10 (50.00%) 
Cost of test is prohibitory, lack of insurance coverage  6 (30.00%) 
Limitation on counselor – time or patient load 4 (20.00%) 
What benefits, if any, have you noticed or perceived since the implementation of Universal NIPS into the 
ACMG screening guidelines, in 2016? (N=47) 
[Comments by theme] 
None or N/A 16 (34.04%) 
Better insurance coverage 9 (19.15%) 
Increased test validity 7 (14.89%) 
Improved access 6 (12.77%) 
Anxiety reduction for patients 5 (10.64%) 
More options 5 (10.64%) 
Patient awareness of NIPS has increased 5 (10.64%) 
Increase in use by providers and knowledge about test specifics 5 (10.64%) 
What issues, if any, do you feel have arisen since the implementation of Universal NIPS into the ACMG 
screening guidelines, in 2016? (N=57) 
[Comments by theme] 
Inadequate or incorrect pre-test counseling 15 (26.32%) 
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No issues or N/A 13 (22.81%) 
Lack of insurance coverage or cost is prohibitory 13 (22.81%) 
Providers lack sufficient or accurate understanding of test specifics  12 (21.05%) 
Miss traditional screening info-analytes or ultrasound 7 (12.28%) 
Test being used to determine sex/gender 7 (12.28%) 
MFM agreement about practice guidelines 6 (10.53%) 
a Subtotal of respondents. b Responses compiled from two questions, “Please explain the 
difference between your practice of not offering NIPS universally and your opinion that it should be offered to 
all patients …” and “Please explain the difference between your practice of offering NIPS universally and 
your opinion that it should not be offered to all patients…”  
 
 
Figure 5. Under what circumstances, in the future, would you choose to offer NIPS for these conditions? 
 
Table VI: Opinions on Future Uses of NIPS 
Question Theme  na(%) 
What additional comments or concerns, if any, do you have with the continued expansion of NIPS into new 
patient populations and conditions? (N=25) 
Patient education needs to improve 12 (48.00%) 
Test validity needs to increase 9 (36.00%) 
Provider education needs to be improved 8 (32.00%) 
Test utility needs to be better established 5 (20.00%) 
Insurance coverage needs to improve, cost of test needs to be reduced 3 (12.00%) 
a Subtotal of respondents.  




Changes over time 
 As we had hypothesized, the opinion of genetic counselors concerning universal 
NIPS has significantly shifted since the 2015 survey by Suskin et al. (Chi-square = 13.02 
(df=1), p<.001). When asked “Do you believe that NIPS should be offered universally (i.e. to any 
pregnant woman, regardless of a priori risk)?” 44.74% (85) of genetic counselors in 2015 stated yes, 
while 67% (67) chose yes in 2018 (Figure 1). Practice has also changed in the last three years. 
Since the Suskin et al. 2015 study, significantly more genetic counselors were offering NIPS 
universally (Chi-Square = 66.94, (df=1), p <.001). Only 10.7% (22) of the genetic counselors 
in the previous study reported offering NIPS to any pregnant woman regardless of risk, 
while 54.2% of the counselors in the current study offered universal NIPS (Figure 2). As per 
our study, a greater number of GCs are also offering NIPS with microdeletions. When asked 
how they currently use NIPS with microdeletion panels 24.0% stated they do not currently 
offer it, this number is down significantly from 2015 when 47.7% reported not offering 
NIPS with microdeletions (Figure 3, Chi-square = 16.89 (df=1), p<.001). One area of 
minimal change was to whom NIPS is offered. Responses were similar for all categories of 
patients except that low-risk patients were more likely to be offered NIPS if they inquired 
about it.  The rate increased from 36.9% in the previous study to 49.0% in the current study. 
This change was in line with the trends noted in this study, but was not statistically 
significant (Chi-square = 2.43 (df=1), p = .12). 
Analysis of coded qualitative data revealed a few significant changes between the two 
studies. When asked about why they support universal NIPS, fewer respondents reported 
feeling the need to emphasize the limitations of NIPS: 11.9% (7) in 2018 versus 27.5% (19) 
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in 2015 (Chi-square = 4.63 (df=1), p<.05). No other codes showed significant difference 
over time vis-à-vis those who support universal NIPS.  
On the other hand qualitative data on those who do not support universal NIPS 
showed several significant differences. Interestingly, the expressed desire for additional 
prenatal screening test values increased from 3.1% (3) in 2015 to 15.8% (3) in 2018 (Fisher’s 
Exact probability <.05). So despite many studies on NIPS offering proof of its validity and 
accuracy, GCs are increasingly concerned about the loss of other screening values with an 
increased use of NIPS. One respondent echoed concerns regarding skipped MSAFP 
screening and NT measurements, saying the following, “we have an office that has had a 
couple of patients with anencephaly that were missed until 20 weeks and multiples not 
diagnosed until 20 weeks. Our office still recommends an NT regardless of which blood test 
a patient chooses.” There was a significant difference in concerns expressed about gender 
and sex, 26.5% (5) in 2018 versus only 1.0% (1) in 2015 (Fisher’s Exact probability, 
.001).  Our results also documented increased public awareness of the test, including its 
ability to detect fetal sex. One respondent wrote: “Most [patients] do [NIPS] for gender. We 
have had couples terminate for gender. NIPT gets them results early enough they can act 
without people knowing they are pregnant...” 
Demographic information versus Study Question 
Demographic data identified some trends. Years in practice were negatively 
correlated with the belief that NIPS should be offered to any pregnant woman regardless of 
a priori risk (Figure 4, r (99) = -.21, p<.05).  Genetic counselors practicing for fewer years 
were more open to the idea of NIPS being offered universally. In fact, 78.4% (29) of those 
practicing less than 3 years were in favor of universal NIPS, while only 45.0% (9) of those 
practicing over 20 years favored universal NIPS.  
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The belief that NIPS should be offered universally was also significantly related to 
the portion of patients GCs see who have coverage through state or federal insurance 
programs (e.g., Medicaid or Medicare) (Chi-square = 8.25 (df=3), p<.05). Counselors 
practicing in institutions where fewer patients were covered by these insurance programs 
were more likely to believe NIPS should be offered to all pregnant women. Comparatively, 
86.4% (19), of respondents with less than 25% of their patients insured through federal or 
state programs, were in favor of universal NIPS, while only 58.97% (46) of those with 25% 
or more of their patients covered under Medicaid, favored universal NIPS. Another note 
about Medicaid coverage, respondents from the same state did not necessarily report 
Medicaid covering the test in the same way. This may indicate that certain labs have policies 
where they absorb any cost associated with a patient on Medicaid, regardless of whether they 
receive reimbursement in order to increase the number of tests ordered.  There was no 
correlation between the percentage of patients who elect to pursue diagnostic testing and 
whether or not respondents think NIPS should be offered universally (Chi-square = 3.09 
(df=2) p=.08). However, GCs who reported less than 25% of their patients pursue 
diagnostic testing, were more likely to report being in favor of universal NIPS [71.2% (47)] 
than those with greater than 25% of patients doing invasive testing [50% (10)].  
Current Practices versus Study Question 
Genetic counselors who work in institutions where NIPS is offered to all patients 
regardless of risk were more likely to believe in offering NIPS universally (Table III, Chi-
square = 33.57 (df=1), p<.001). While 92.3% (48) of those who currently offer NIPS to all 
patients believe in universal NIPS, 36.4% (16) of those who do not offer NIPS to all 
reported that they are in favor of universal access. Data reflects significant dissonance 
remaining between counselors’ beliefs and actions.  
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“To whom do you offer NIPS? (Select all that apply),” was asked of all respondents who 
reported not offering NIPS universally. Almost all stated that they offer NIPS to patients 
over 35, patients with a high-risk screen, and patients with a previous pregnancy affected 
with an aneuploidy. Very few reported offering NIPS to patients with a family history of 
other genetic conditions, patients interested in early detection of fetal sex, or patients with 
recurrent miscarriage. These trends did not correlate with opinion of offering NIPS 
universally.    
An additional question inquired about which subtypes of NIPS GCs offer to all 
patients. In comparing responses from participants who believe in universal NIPS against 
those who do not, significant differences were identified. The difference was significant in 
regards to those offering sex chromosomes (Table IV, Chi-square=15.61, p<.001), with 
75.00% of those who support universal NIPS and 32.26% who do not support universal 
NIPS offering sex chromosomes to all patients. It is also significant for those offering 
limited microdeletion panels (Table IV, Chi-square=6.58, p<.05), with 25.42% and 3.33% of 
those who do and do not support universal NIPS respectively offering these panels to all 
patients.   
Discordance between practice and opinion 
 Two questions were drafted in an attempt to parse out the differences between the 
20.83% (20) of genetic counselors whose beliefs and practices do not align. One question 
was asked of those who support universal NIPS, but do not offer it to all patients, the other 
was asked to those who do not support universal NIPS, but offer it universally. Qualitative 
responses revealed themes including that the decision was made by other people (50%, 
n=10), the cost of the test and lack of insurance coverage (30%, n=6), and the inability for 
genetic counselors to accommodate all patients (20%, n=4) (Table V). In comparing the 
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2015 and the 2018 studies, the majority of counselors reported their beliefs aligning with the 
practice at their institution, 64.73% (123), in 2015, and 79.17% (76), in 2018 (Table III). 
However, there was a significant change in the number of counselors who believe that the 
universal use of NIPS is appropriate and worked in institutions in which all prenatal patients 
are offered NIPS. The number of respondents jumped from 23.5% (20) in the previous 
study to 75.0% (48) in the current study (Chi-square = 39.00 (df=1), p<.001). In 2018, a 
greater number of GCs reported believing NIPS should not be offered universally and 
working in an institution that offers NIPS to all patients, 12.5% (4) than in 2015 when only 
1.9% (2) of respondents reported this.  
Support of Universal NIPS 
The 58 qualitative responses to the question “Please explain why you think NIPS should 
be offered universally …” were coded by consensus identifying four major and three minor 
themes (Table V). An additional question of “What benefits, if any, have you noticed or perceived 
since the implementation of Universal NIPS into the ACMG screening guidelines, in 2016?” had 47 
responses which were also analyzed for common themes; eight major and two minor themes 
were identified (Table V).  
Those who supported the use of universal NIPS often made statements about how 
NIPS has superior validity than traditional screening, including higher specificity, higher 
sensitivity, and lower false positive rate. Of those who said NIPS should be offered to all 
patients regardless of risk, 74.58% (44) discussed the superiority of NIPS to other available 
screening tests. One GC stated, “... studies suggest that the sensitivity/specificity of the 
testing in average-risk populations is likely very similar to that in high-risk populations, and 
it's a far superior test to conventional serum screening,” while another succinctly stated, “It's 
the best screen available. It has the highest detection rate and the lowest false positive- why 
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not offer it everyone [sic]?” This theme illustrates genetic counselors’ comfort with relying 
on the data in order to determine which screening test to offer. This theme also emerged in 
another question that asked respondents to discuss benefits they have noticed since the 
implementation of universal NIPS screening into ACMG guidelines with 14.89% (7) of GCs 
saying improvements have been made in test analytical validity. An example of this opinion 
“Fewer false positive than other serum screens, this change has been FABULOUS!” 
demonstrates the excitement some genetic counselors feel about the changes NIPS have 
brought about.  
Of GCs who supported the use of NIPS for all patients in the current study, 18.64% 
(11) advocated that offering the screening to all women should be our way of presenting 
options in an unbiased manner and expanding access to care. One participant pointed out 
“[NIPS] will expand high quality screening access to individuals who don't have access to 
first trimester ultrasounds with accurate NT/NB measurements.” Another noted, “By not 
offering it to everyone we become more paternalistic.” In describing the benefits, 23.4% (11) 
genetic counselors expressed having more choices and improved access for patients. One 
wrote, “I love how even patients who miss our ‘1st tri window’ can still get the best 
screening and not have to settle for a Quad with an increased risk for false positive.”  
 Pre-test counseling was mentioned by a minority 11.86% (7) of GCs offering 
comments. One respondent stated, “It should be offered and carefully explained by a genetic 
counselor. There are nuances to the data on low risk groups, multiples, egg donor 
pregnancies. Also, insurance coverage is an issue for some patients, especially those in the 
low risk category,” which emphasized the way genetic counselors are uniquely equipped to 
discuss these diverse topics and provide accurate information.   
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Genetic counselors who believe NIPS should be offered to all patients, 11.86% (7) 
commented on perceived limitations of the test and how that affected their opinions of its 
use. For example, one respondent said, “Less false positives than first trimester or quad 
screening. However I don't think that NIPS with microdeletions should be offered to 
everyone due to the low PPVs.” This exemplifies the common idea that NIPS should be 
provided universally for the traditional trisomies, though in the opinions of these GCs, not 
for every condition. Another counselor similarly said, “I believe it is one of the best 
screening tools we have currently for the common aneuploidies, and we should approach it 
in the same way we have approached first trimester screening. However, it is worth noting 
that I only feel that universal screening for Trisomy 13, Trisomy 18, and Trisomy 21 should 
be offered - NOT microdeletions/duplications, genome-wide copy number variants, or 
single gene disorders.” 
Do not support universal NIPS 
Responses to “Please explain why you think NIPS should not be offered universally …” were 
analyzed for common themes. From the nineteen answers, coded by consensus, six themes 
were identified (Table V). Other qualitative responses that were critical to universal NIPS 
were in response to “What issues, if any, do you feel have arisen since the implementation of Universal 
NIPS into the ACMG screening guidelines, in 2016?” This question was also coded by consensus, 
and from the 57 responses ten common themes were identified (Table V).  
In a striking comparison to supporters of universal access, GCs who do not believe 
NIPS should be offered to all patients stated that NIPS is not better than other screens or 
data does not suggest its universal expansion is beneficial, with 73.68% (14) raising such 
concerns. One stated, “PPV for most conditions is still very low with low risk patients,” 
demonstrating concern with clinical utility. Others did not state that the values are too low, 
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but rather that there are “Limited studies in low risk population Limited PPV in low risk 
population Limited sensitivity for microdels, sex chromosome aneuploidy.”  
Gender and sex, or the use of NIPS for detecting it, were a popular point of 
contention for GCs who do not believe in universal NIPS. This was brought up by 26.32% 
(5) of respondents against universal NIPS, including one who wrote: “I have no problem 
with it being offered to everyone if people are choosing it for the real reason of aneuploidy 
screening and not for determining gender.” This theme was also identified by 12.28% (7) of 
respondents when asked about issues that have arisen since the ACMG inclusion of 
universal NIPS into their guidelines, despite specification the test should not be used for sex 
selection (Gregg et al. 2016).  
Hesitation about the expansion of NIPS to all patients and for a larger range of 
conditions was at least partially related to cost. GCs who do not believe in offering NIPS to 
all patients indicated insurance coverage was a concern in 21.05% (4) of responses. This 
reasoning was often combined with other issues, much as it was here: “For women under 35, 
a first trimester screen has almost as high detection rate as NIPS at half the cost...Test 
utilization is important in the grand scheme of healthcare. Unnecessarily spending thousands 
of dollars adds to the system in general and compounds the problem. The difference 
between a 96% detection rate and 99.99% one is there, but I don't believe it's big enough for 
me to consider doing NIPS on all patients. Not unless the cost of NIPS drastically reduces.” 
Willingness of insurance to cover testing was a frustration expressed by 22.81% (13) of those 
who identified issues since the ACMGs inclusion of universal NIPS. In the case of this 
second question, some respondents explained that “despite the ACMG guideline, ACOG 
does not concur and insurance does not cover this testing,” showing there is still work that 
must be done before insurance coverage will cover universal NIPS.   
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Desire for values from non-NIPS screening tests was brought up by 15.79% (3) of 
respondents. An example that reflects this was, “I ultimately think we should move to 
genome wide NIPS for all pregnant patients but still think biochemical screening (AFP, uE3, 
hCG) has usefulness if it would be incorporated with NIPS for screening for adverse 
outcome or specific conditions (ONTD [open neural tube defects], SLO [Smith-Lemli-
Opitz], abdominal wall defects, etc).” The survey also identified that 61.05% (58) of genetic 
counselors combine NIPS with other aneuploidy screening. Of those that use additional 
screening, 98.83% (55) combine NIPS with NT. While the survey did not include level 2 
anatomy scan as a type of aneuploidy screening, several respondents included it under the 
“other” option.  
Of those who do not believe in the use of universal NIPS, 15.79% (3) plainly stated 
concerns, such as, “Lack of knowledge of offering providers”. In discussing issues associated 
with the shifting 2016 ACMG guidelines, GCs specifically referenced a lack of understanding 
and inaccurate knowledge provision by obstetricians and gynecologists. Specifically, this 
counselor explained their experience: “Doctors tell their patients that the screening is 
INSTEAD of amnio/cvs. Or at least that's what patients are hearing. And I have actually 
heard MDs say, ‘This blood draw will tell us if everything is okay with the baby's 
chromosomes’ or ‘There’s now a blood test that tells us the same thing the amnio does.’ 
VERY DANGEROUS. MDs need to be properly educated. Or be willing to explain to pts 
why an aneuploidy was missed.” More succinctly, another counselor gave this opinion, “I 
also think that most general OB providers don't understand the concepts of sensitivity, 
specificity, positive predictive value.” 
A few of the genetic counselors, 15.79% (3), included in their responses, statements 
about universal NIPS being an inevitable fact of the future. Quotes such as “[universal 
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NIPS] will likely be the case within a few years …,” often included stipulations about how 
they wish universal NIPS would be implemented, and were linked with provider knowledge 
and other screening values.  
Future   
Participating GCs were asked under what circumstances they would be willing to 
offer different methods of genetic information analysis by NIPS in the future. The question 
gave genetic counselors the option of stating they would never use a specific subset of NIPS. 
Of the test options, which included microdeletions (limited panel), early pregnancy loss, 
whole genome copy number variant screening, single gene disorder panel, whole exome, and 
whole genome, the only test type which no respondents reported they would never use was 
the limited microdeletion panel (Figure 5). In relation to the limited microdeletion panel, the 
majority of respondents (73.42%) stated they would be willing to offer it in the future if 
there were increased test validity (sensitivity, specificity, PPV).  
Study Limitations 
This survey was distributed through the NSGC listserv. The open rate was 26.8% 
(967) and 23% (838) for the reminder email; as with any study the people who respond are 
the most interested in the topic. One error in our survey logic may have resulted in a drop 
off of responses by asking respondents a question that did not apply to them, only 
qualitative data was affected. Another survey logic error had a number of GCs skip a 
question, resulting in a lower number of responses for a qualitative question. Of note both 
errors were corrected within a half hour of the survey being released, and no quantitative 
data was affected. Also in general, self reported data may result in skewed results due to the 
respondents answering how they think they should, instead of what they actually do and 
think, or interpreting the question in a way that was different than it was intended when 
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written. Also quantitative data collected by self-reporting may be subject to misperceptions 
by the GC such as overestimation or underestimation of a fact. In future studies, question 
design should be undertaken with care in order to better analyze the data, especially in asking 
about current use of NIPS. A more effective way to ask would be to first ask if they offer the 
type of test, then whether they offer it to everyone, followed by to whom do they offer it, as 
to avoid conflicting responses.  
CONCLUSION 
Although a majority of genetic counselors believe that NIPS should be offered to all 
patients, and our study suggests significantly more GCs are offering NIPS universally than in 
2015, we still do not see a consensus on how and when to offer it. Especially in relation to 
whether NIPS is offered in isolation or in conjunction with additional screening tests, as only 
about 60% of respondents reported offering it with other screening methods. NIPS 
technology can now be used to detect a wider range of genetic abnormalities. However, 
counselors are still not in agreement as to what constitutes the appropriate use of these 
expanded NIPS panels. Guidelines put forth by the ACMG support offering NIPS as a 
choice for all pregnant women, but this is change has not been mirrored by other 
professional organizations. Until practice guidelines are in agreement and use is in alignment 
with practice guidelines, the issues of how and who best to offer NIPS will most likely 
remain unsettled. Research on genetic counselors practice and opinions should continue to 
help inform standard of care implementation for prenatal screening.   
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Questions Answers na(%) 
Are you a certified genetic counselor? (N=103) 
Yes 103 (100%) 
No 0 (0.00%) 
How many years have you been a practicing GC? (in years) (N=103) 
Less than 3  37 (35.92%) 
3 - 4 6 (5.83%) 
5 - 6 10 (9.71%) 
7 - 10 10 (9.71%) 
11 - 15 7 (6.80%) 
16 - 20 13 (12.62%) 
More than 20 20 (19.42%) 
In what country do you work? (N=103) 
United States 99 (96.12%) 
Canada 3 (2.91%) 
                                                                                 Other (Please Specify)  
Australia 
1 (0.97%) 
In which NSGC practice region do you work? b, c (N=100) 
Region 1 11 (11.00%) 
Region 2 18 (18.00%) 
Region 3 8 (8.00%) 
Region 4 34 (34.00%) 
Region 5 6 (6.00%) 
Region 6 24 (24.00%) 
On average how many prenatal patients do you counsel in a week? (N=103) 
< 5 10 (9.71%) 
5 - 9 21 (20.39%) 
10 - 14 31 (30.10%) 
15 - 19 29 (28.16%) 
≥ 20 12 (11.65%) 
Which of these best describes your primary work place? (N=100) 
University Medical Center 40 (40.00%) 
Private Practice 18 (18.00%) 
Private Hospital 18 (18.00%) 
Public Hospital 14 (14.00%) 
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Community Hospital 2 (2.00%) 
Diagnostic Laboratory - Commercial 2 (2.00%) 
Health Maintenance Organization (HMO) 2 (2.00%) 
Government or Military Center 0 (0.00%) 
Other (please specify) 
Non-profit 
Private MFM office 





In what setting do you primarily practice? (N=102) 
Urban 65 (63.73%) 
Suburban 33 (32.35%) 
Rural 4 (3.92%) 
Approximately what portion of your patients have coverage through state or federal insurance programs 
(Medicaid or Medicare)? (N=100) 
< 25% 22 (22.00%) 
25 - 49% 47 (47.00%) 
50 - 75% 22 (22.00%) 
> 75% 9 (9.00%) 
Approximately what percentage of the patients offered NIPS at your center/institution are seen by genetics 
prior to testing? (N=94) 
< 25% 15 (15.96%) 
25 - 49% 5 (5.32%) 
50 - 75% 13 (13.83%) 
> 75% 61 (64.89%) 
a Subtotal of respondents. bNSGC practice regions are defined as follows: 
Region 1: CT, MA, ME, NH, RI, VT, CN Maritime Provinces  
Region 2: DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec  
Region 3: AL, FL, GA, KY, LA, MS, NC, SC, TN 
Region 4: AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario  
Region 5: AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Saskatchewan  
Region 6: AK, CA, HI, ID, NV, OR, WA, British Columbia 
c Responses calculated based on two questions, “In which American state/territory do you 
primarily work?” and “In which Canadian province/territory do you primarily practice?” 
  




Current Practices and Opinions 
Questions Answers  na (%) 
Do you believe that NIPS should be offered universally (i.e. to any pregnant woman, regardless of a priori 
risk)? (N = 100) 
Yes 67 (67.00%) 
No 33 (33.00%) 
Please explain why you think NIPS should be offered universally … (N=58) 
[Comments by theme on the belief that NIPS should be offered universally] 
NIPS is superior to traditional screening options  44 (74.58%) 
Offer all screening choices 11 (18.64%) 
Need for pre-test counseling by GC 7 (11.86%) 
Emphasis placed on limitations of NIPS 7 (11.86%) 
Women <35 are still at risk of having affected pregnancy  4 (6.78%) 
NIPS should be provided with NT and/or LII 3 (5.08%) 
NIPS provides flexibility of timing 3 (5.08%) 
Please explain why you think NIPS should not be offered universally…(N=19) 
[Comments on disagreement with offering NIPS universally by theme] 
Data does not show superior test validity in low-risk populations 13 (68.34%) 
Use of test to detect gender/sex 5 (26.32%) 
Lack of insurance coverage, cost is prohibitory 4 (21.05%) 
Want values from other screening 3 (15.79%) 
Providers do not have sufficient or accurate knowledge about NIPS 3 (15.79%) 
NIPS will be universal in the future, inevitable 3 (15.79%) 
Does your institution currently offer NIPS? (N=98) 
Yes 97 (98.98%) 
No 1 (1.02%) 
Do you offer NIPS to ALL patients, regardless of risk? (N=96)   
Yes 52 (54.17%) 
No 44 (45.83%) 
Please explain the difference between your practice of not offering NIPS universally and your opinion that it 
should be offered to all patients … (N=16)  
[Responses by theme]  
Decision was made by others are the institution/practice 7 (43.75%) 
Lack of insurance coverage, cost prohibitory 6 (37.50%) 
Limitation of counselor - time or patient load 3 (18.75%) 
Doctor's decision, some offer universally, others do not  2 (12.50%)  
Disagree with practice, but did not state whose decision it was 2 (12.50%) 
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Other screening values wanted 1 (6.25%) 
Please explain the difference between your practice of offering NIPS universally and your opinion that it 
should not be offered to all patients…(N=4) 
[Responses by theme] 
Fear of inadequate patient education and consenting 3 (75.00%) 
Traditional Screening is effective as a first line test 3 (75.00%) 
Cost of test is prohibitory 2 (50.00%) 
Knowledge gap of doctors and other providers 2 (50.00%) 
To whom do you offer NIPS? (Select all that apply)b (N=46)  
Patients with a high-risk screen (NT, FTS, Quad, Sequential) 46 (100.00%) 
Patients over 35 44 (95.65%) 
Patients with a previous pregnancy affected with an aneuploidy 44 (95.65%) 
Patients who inquire about the test 24 (52.17%) 
Patients with recurrent miscarriage 8 (17.39%) 
Patients with family history of other genetic conditions 6 (13.04%) 
Patients interested in early detection of fetal sex 5 (10.87%) 




Do you generally combine the use of NIPS with other aneuploidy screening options? (N=95) 
Yes 58 (61.05%) 
No 37 (38.95%) 
What additional screening do you offer to patients who pursue NIPS? (Select all that apply)c (N=58) 
Nuchal Translucency (NT)  55 (98.83%) 
AFP maternal serum screen 39 (67.24%) 
First trimester screening of analytes 18 (31.03%) 
Quad screen 12 (20.69%) 
Sequential screen 9 (15.52%) 




Assuming NIPS was performed with MSAFP, which of the following would you be concerned about losing in 
a transition to NIPS as primary screening? (Please select all that apply) (N=95) 
NT (Nuchal Translucency) 78 (82.11%) 
PAPP-A (pregnancy associated plasma protein A) 31 (32.63%) 
uE3 (unconjugated estriol) 27 (28.42%) 
hCG (free beta human chorionic gonadotropin or intact/total human 
chorionic gonadotropin) 
15 (15.79%) 
Inhibin-A 7 (7.37%) 
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None 14 (14.74%) 
What do you recommend first to patients who receive no-call results on NIPS? (N=87) 
Redraw sample with the same lab 43 (49.43%) 
Offer diagnostic testing 18 (20.69%) 
Redraw sample to send to a different lab 0 
Increased ultrasound/early anatomy scan 0 
No action taken/Do not recommend further testing 0 
Other (please specify) 










1 (1.15%)  
Please explain your current use of NIPS for each category of conditions? Classic Aneuploidy Screening 
(Trisomy 13, Trisomy 18, Trisomy 21) (N=91) 
Must be performed if test is ordered 47 (51.65%) 
Offered to all patients 45 (49.45%) 
Offered to high-risk patients (AMA, positive screen)  54 (59.34%) 
Offered to patients with u/s findings 53 (58.24%) 
Offered to patients with family history of condition 40 (43.96%) 
Only offered if patient asks 11 (12.09%) 
Offered to patients with history of multiple miscarriage 11 (12.09%) 
Offered for research purposes 0 (0.00%) 
Not currently offered at this center  0 (0.00%) 
Please explain your current use of NIPS for each category of conditions? Sex Chromosomes (N=91) 
Must be performed if test is ordered 15 (16.48%) 
Offered to all patients  55 (60.44%) 
Offered to high-risk patients (AMA, positive screen) 47 (51.65%) 
Offered to patients with u/s findings 43 (47.25%) 
Offered to patients with family history of condition 34 (37.36%) 
Only offered if patient asks 12 (13.19%) 
Offered to patients with history of multiple miscarriage 6 (6.59%) 
Offered for research purposes  0 (0.00%) 
Not currently offered at this center  0 (0.00%) 
Please explain your current use of NIPS for each category of conditions? Early Pregnancy Loss 
Chromosomes  (Trisomy 9, Trisomy 16, Trisomy 22) (N=85) 
Must be performed if test is ordered 1 (1.18%) 
Offered to all patients 8 (9.41%) 
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Offered to high-risk patients (AMA, positive screen)  6 (7.06%) 
Offered to patients with u/s findings 13 (15.29%) 
Offered to patients with family history of condition 15 (17.65%) 
Only offered if patient asks 8 (9.41%) 
Offered to patients with history of multiple miscarriage 12 (14.12%) 
Offered for research purposes 0 (0.00%) 
Not currently offered at this center  53 (62.35%) 
Please explain your current use of NIPS for each category of conditions? Microdeletion Syndromes (limited 
panel) (N=89) 
Must be performed if test is ordered 1 (1.12%) 
Offered to all patients 16 (17.98%) 
Offered to high-risk patients (AMA, positive screen) 11 (12.36%) 
Offered to patients with u/s findings 42 (47.19%) 
Offered to patients with family history of condition 33 (37.08%) 
Only offered if patient asks 22 (24.72%) 
Offered to patients with history of multiple miscarriage 2 (2.25%) 
Offered for research purposes 0 (0.00%) 
Not currently offered at this center  23 (25.84%) 
Please explain your current use of NIPS for each category of conditions? Whole Genome Copy Number 
Variant Screening (N=88) 
Must be performed if test is ordered 0 (0.00%) 
Offered to all patients  1 (1.14%) 
Offered to high-risk patients (AMA, positive screen) 4 (4.55%) 
Offered to patients with u/s findings 31 (35.23%) 
Offered to patients with family history of condition 16 (18.18%) 
Only offered if patient asks   7 (7.95%) 
Offered to patients with history of multiple miscarriage 7 (7.95%) 
Offered for research purposes 0 (0.00%) 
Not currently offered at this center  50 (56.82%) 
Please explain your current use of NIPS for each category of conditions? Single gene conditions (N=89) 
Must be performed if test is ordered 0 (0.00%) 
Offered to all patients 0 (0.00%) 
Offered to high-risk patients (AMA, positive screen) 1 (1.12%) 
Offered to patients with u/s findings 24 (26.97%) 
Offered to patients with family history of condition 20 (22.47%) 
Only offered if patient asks 11 (12.36%) 
Offered to patients with history of multiple miscarriage 0 (0.00%) 
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Offered for research purposes 1 (1.12%) 
Not currently offered at this center  55 (61.80%) 
Approximately what is the uptake of patients who are offered this type of testing? Classic Aneuploidy 
Screening (Trisomy 13, Trisomy 18, Trisomy 21) (N=89) 
< 25% 2 (2.25%) 
25 - 49% 7 (7.87%) 
50 -74% 21 (23.60%) 
> 75% 59 (66.29%) 
N/A - not offered 0 (0.00%) 
Approximately what is the uptake of patients who are offered this type of testing? Sex Chromosomes 
(N=89) 
< 25% 4 (4.49%) 
25 - 49% 5 (5.62%) 
50 -74% 29 (32.58%) 
> 75% 50 (56.18%) 
N/A - not offered 1 (1.12%) 
Approximately what is the uptake of patients who are offered this type of testing? Early Pregnancy Loss 
Chromosomes  (Trisomy 9, Trisomy 16, Trisomy 22) (N=89) 
< 25% 14 (15.73%) 
25 - 49% 4 (4.49%) 
50 -74% 6 (6.74%) 
> 75% 5 (5.62%) 
N/A - not offered 60 (67.42%) 
Approximately what is the uptake of patients who are offered this type of testing? Microdeletion Syndromes 
(limited panel) (N=87) 
< 25% 20 (22.99%) 
25 - 49% 13 (14.94%) 
50 -74% 11 (12.64%) 
> 75% 12 (13.79%) 
N/A - not offered 31 (35.63%) 
Approximately what is the uptake of patients who are offered this type of testing? Whole Genome Copy 
Number Variant screening  (N=89) 
< 25% 21 (23.60%) 
25 - 49% 7 (7.87%) 
50 -74% 3 (3.37%) 
> 75% 5 (5.62%) 
N/A - not offered 53 (59.55%) 
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Approximately what is the uptake of patients who are offered this type of testing? Single gene conditions 
(N=89) 
< 25% 22 (24.72%) 
25 - 49% 3 (3.37%) 
50 -74% 2 (2.25%) 
> 75% 4 (4.49%) 
N/A - not offered 58 (65.17%) 
Under what circumstances does Medicaid cover NIPS for these conditions? Classic Aneuploidy Screening 
(N=78) 
Coverage of all patients 15 (19.23%) 
Coverage of patients over 35 40 (51.28%) 
Coverage only if family history or history of previous affected pregnancy 21 (26.92%) 
Coverage only if ultrasound findings 25 (32.05%) 
Coverage if high-risk by screening 34 (43.59%) 
No Coverage 12 (15.38%) 
N/A 8 (10.26%) 
Under what circumstances does Medicaid cover NIPS for these conditions? Sex Chromosomes  (N=76) 
Coverage of all patients 15 (19.74%) 
Coverage of patients over 35 27 (35.53%) 
Coverage only if family history or history of previous affected pregnancy 14 (18.42%) 
Coverage only if ultrasound findings 16 (21.05%) 
Coverage if high-risk by screening 21 (27.63%) 
No Coverage 19 (25.00%) 
N/A 13 (17.11%) 
Under what circumstances does Medicaid cover NIPS for these conditions? Microdeletion Syndromes (limited 
panel) (N=76) 
Coverage of all patients 7 (9.21%) 
Coverage of patients over 35 10 (13.16%) 
Coverage only if family history or history of previous affected pregnancy 11 (14.47%) 
Coverage only if ultrasound findings 11 (14.47%) 
Coverage if high-risk by screening 10 (13.16%) 
No Coverage 28 (36.84%) 
N/A 26 (34.21%) 
Under what circumstances does Medicaid cover NIPS for these conditions? Early Pregnancy Loss (N=74) 
Coverage of all patients 1 (1.35%) 
Coverage of patients over 35  2 (2.70%) 
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Coverage only if family history or history of previous affected pregnancy 1 (1.35%) 
Coverage only if ultrasound findings 1 (1.35%) 
Coverage if high-risk by screening  1 (1.35%) 
No Coverage 27 (36.49%) 
N/A 42 (56.76%) 
Under what circumstances does Medicaid cover NIPS for these conditions? Whole Genome Copy Number 
Variant Screening (N=77) 
Coverage of all patients 1 (1.30%) 
Coverage of patients over 35 2 (2.60%) 
Coverage only if family history or history of previous affected pregnancy 4 (5.19%) 
Coverage only if ultrasound findings 5 (6.49%) 
Coverage if high-risk by screening 3 (3.90%) 
No Coverage 29 (37.66%) 
N/A 40 (51.95%) 
Under what circumstances does Medicaid cover NIPS for these conditions? Single gene conditions (N=75) 
Coverage of all patients 0 (0.00%) 
Coverage of patients over 35 0 (0.00%) 
Coverage only if family history or history of previous affected pregnancy 4 (5.33%) 
Coverage only if ultrasound findings 2 (2.67%) 
Coverage if high-risk by screening 1 (1.33%) 
No Coverage 28 (37.33%) 
N/A 42 (56.00%) 
Approximately what percent of patients have diagnostic testing? (Amniocentesis or CVS) (N=86) 
< 25% 66 (76.74%) 
25 - 49% 14 (16.28%) 
50 - 74% 4 (4.65%) 
> 75% 2 (2.33%) 
How frequently is diagnostic testing pursued for the following reason? Positive or high-risk NIPS results 
(N=86) 
Never 0 (0.00%) 
Rarely 2 (2.33%) 
Sometimes 14 (16.28%) 
Often 70 (81.40%) 
How frequently is diagnostic testing pursued for the following reason? Positive or high-risk aneuploidy screen 
(FTS or Quad)  (N=86) 
Never 3 (3.49%) 
Rarely 32 (37.21%) 
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Sometimes 42 (48.84%) 
Often 9 (10.47%) 
How frequently is diagnostic testing pursued for the following reason? Conflicting screening results (N=85) 
Never 6 (7.06%)  
Rarely 22 (25.88%) 
Sometimes 39 (45.88%) 
Often 18 (21.18%) 
How frequently is diagnostic testing pursued for the following reason? Advanced Maternal Age  (N=86) 
Never 6 (6.98%) 
Rarely 45 (52.33%) 
Sometimes 32 (37.21%) 
Often 3 (3.49%) 
How frequently is diagnostic testing pursued for the following reason? Desire for microarray 
testing  (N=86) 
Never 9 (10.79%) 
Rarely 30 (34.88%) 
Sometimes  28 (32.56%) 
Often 19 (22.09%) 
How frequently is diagnostic testing pursued for the following reason? Parental Anxiety (N=85) 
Never 12 (14.12%) 
Rarely 46 (54.12%) 
Sometimes 24 (28.24%) 
Often 3 (3.53%) 
How frequently is diagnostic testing pursued for the following reason? Ultrasound findings (N=86) 
Never 1 (1.16%) 
Rarely 3 (3.49%) 
Sometimes 26 (30.23%) 
Often 56 (65.12%) 
How frequently is diagnostic testing pursued for the following reason? Family history of condition / parent is 
carrier of condition (N=86) 
Never 1 (1.16%) 
Rarely 13 (15.12%) 
Sometimes  40 (46.51%) 
Often 32 (37.21%) 
How frequently is diagnostic testing pursued for the following reason? Residual risk of aneuploidy after 
negative NIPS result (N=86) 
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Never 26 (30.23%) 
Rarely 55 (63.95%) 
Sometimes 5 (5.81%) 
Often 0 (0.00%) 
How frequently is diagnostic testing pursued for the following reason? No call or Inconclusive results on 
NIPS (N=86) 
Never 6 (6.98%) 
Rarely 40 (46.51%) 
Sometimes 37 (43.02%) 
Often 3 (3.49%) 
What is the most common reason patients pursue diagnostic testing (N=86) 
Ultrasound findings 41 (47.67%) 
Positive or high-risk NIPS results 38 (44.19%) 
Positive or high-risk aneuploidy screen (FTS or Quad) 3 (3.49%) 
Advanced maternal age 2 (2.33%) 
Parental anxiety 1 (1.16%) 
Desire for microarray testing 1 (1.16%) 
Conflicting screening results 0 
Residual risk of aneuploidy with negative NIPS results 0 
Family history of condition/ parent is carrier of condition 0 
No-call or inconclusive NIPS 0 
Other (please specify) 0 
In your experience, how has the prevalence of the following changed since the implementation of NIPS? 
Invasive diagnostic procedures (CVS/Amniocentesis) (N=85) 
Decreased 58 (68.24%) 
Stayed the Same 9 (10.59%) 
Increased 4 (4.71%) 
Unable to Judge 14 (16.47%) 
In your experience, how has the prevalence of the following changed since the implementation of NIPS? 
Abortion or Selective Termination (N=85) 
Decreased 4 (4.71%) 
Stayed the Same 51 (60.00%) 
Increased 4 (4.71%) 
Unable to Judge 26 (30.59%) 
In your experience, how has the prevalence of the following changed since the implementation of NIPS? 
Children born at specialized care facility (N=85)  
Decreased 0 (0.00%) 
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Stayed the Same 29 (34.12%) 
Increased 20 (25.53%) 
Unable to Judge 36 (42.35%) 
What benefits, if any, have you noticed or perceived since the implementation of Universal NIPS into the 
ACMG screening guidelines, in 2016?…(N=47) 
[Comments on perceived benefits with the implementation of Universal NIPS into the 
ACMG screening guidelines by theme] 
None or N/A 16 (34.04%) 
Better insurance coverage 9 (19.15%) 
Increased test validity 7 (14.89%) 
Improved access 6 (12.77%) 
Anxiety reduction for patients 5 (10.64%) 
More options 5 (10.64%) 
Patient awareness of NIPS has increased 5 (10.64%) 
Increase in use by providers and knowledge about test specifics 5 (10.64%) 
Fewer diagnostic tests 3 (6.38%) 
Guideline discrepancy, ACOG/SMFM do not support universal NIPS 3 (6.38%) 
Earlier detection rate  2 (4.26%) 
What issues, if any, do you feel have arisen since the implementation of Universal NIPS into the ACMG 
screening guidelines, in 2016? (N=57) 
[Comments on issues that have arisen since the implementation of Universal NIPS into the 
ACMG screening guidelines by theme] 
Inadequate or incorrect pre-test counseling 15 (26.32%) 
No issues or N/A 13 (22.81%) 
Lack of insurance coverage or cost is prohibitory 13 (22.81%) 
Providers lack sufficient or accurate understanding of test specifics  12 (21.05%) 
Miss traditional screening info-analytes or ultrasound 7 (12.28%) 
Test being used to determine sex/gender 7 (12.28%) 
MFM agreement about practice guidelines 6 (10.53%) 
Increased Patient Anxiety 5 (8.77%) 
Increase in patient load 3 (5.26%) 
Reduced diagnostic testing 2 (3.51%) 
More diagnostic tests 1 (1.75%) 
a Subtotal of respondents. b This question was only asked to those who stated they do not 
offer NIPS to all patients. c This questions was only asked to those who stated they do 
combine NIPS with other aneuploidy screening.  
 
  




Future Uses and Opinions  
Question Answers  na(%) 
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Microdeletions 
(Limited Panel) (N=79) 
If it becomes standard of care/is integrated into screening 
guidelines 
34 (43.04%) 
If it is covered by insurance 21 (26.58%) 
Test becomes clinically available 3 (3.80%) 
Increased test validity (Sensitivity, Specificity, PPV)  58 (73.42%) 
Under certain circumstances (i.e. suspected diagnosis on 
ultrasound, carrier status, APA, or MCA)  
37 (46.84%) 
Already offer this test  24 (30.38%) 
Never 0 (0.00%) 
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Early 
Pregnancy Loss (N=77) 
If it becomes standard of care/is integrated into screening 
guidelines 34 (44.16%) 
If it is covered by insurance 20 (25.97%) 
Test becomes clinically available 7 (9.09%) 
Increased test validity (Sensitivity, Specificity, PPV)  30 (38.96%) 
Under certain circumstances (i.e. suspected diagnosis on 
ultrasound, carrier status, APA, or MCA)  19 (24.68%) 
Already offer this test  10 (12.99%) 
Never 14 (18.18%) 
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Whole 
Genome Copy Number Variant screening  (N=79) 
If it becomes standard of care/is integrated into screening 
guidelines 32 (40.51%) 
If it is covered by insurance 26 (32.91%) 
Test becomes clinically available 6 (7.59%) 
Increased test validity (Sensitivity, Specificity, PPV)  49 (62.03%) 
Under certain circumstances (i.e. suspected diagnosis on 
ultrasound, carrier status, APA, or MCA)  44 (55.70%) 
Already offer this test  10 (12.66%) 
Never 6 (7.59%) 
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Single Gene 
Disorder Panel (N=80) 
If it becomes standard of care/is integrated into screening 32 (40.00%) 




If it is covered by insurance 30 (37.50%) 
Test becomes clinically available 12 (15.00%) 
Increased test validity (Sensitivity, Specificity, PPV)  51 (63.75%) 
Under certain circumstances (i.e. suspected diagnosis on 
ultrasound, carrier status, APA, or MCA)  51 (63.75%) 
Already offer this test  7 (8.75%) 
Never 1 (1.25%) 
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Whole 
Exome  (N=79) 
If it becomes standard of care/is integrated into screening 
guidelines 30 (37.97%) 
If it is covered by insurance 26 (32.91%) 
Test becomes clinically available 20 (25.32%) 
Increased test validity (Sensitivity, Specificity, PPV)  41 (51.90%) 
Under certain circumstances (i.e. suspected diagnosis on 
ultrasound, carrier status, APA, or MCA)  45 (56.96%) 
Already offer this test  1 (1.27%) 
Never 13 (16.46%) 
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Whole 
Genome  (N=79) 
If it becomes standard of care/is integrated into screening 
guidelines 29 (36.71%) 
If it is covered by insurance 23 (29.11%) 
Test becomes clinically available 18 (22.78%) 
Increased test validity (Sensitivity, Specificity, PPV)  38 (48.10%) 
Under certain circumstances (i.e. suspected diagnosis on 
ultrasound, carrier status, APA, or MCA)  37 (46.84%) 
Already offer this test  1 (1.27%) 
Never 21 (26.58%) 
What additional comments or concerns, if any, do you have with the continued expansion of NIPS into new 
patient populations and conditions? (N=25) 
[Additional comments on the continued expansion of NIPS to new patient populations and 
conditions by theme] 
Patient education needs to improve 12 (48.00%) 
Test validity needs to increase 9 (36.00%) 
Provider education needs to be improved 8 (32.00%) 
Test utility needs to be better established 5 (20.00%) 
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Insurance coverage needs to improve, cost of test needs to 
be reduced 3 (12.00%) 
Lab secrecy should be ended 2 (8.00%) 
Miss traditional screening value(s) 2 (8.00%) 
Future usefulness 1 (4.00%) 
a Subtotal of respondents. 
 
 
 
